Assessment of the relationship between semaphorin4D level and recurrence after catheter ablation in paroxysmal atrial fibrillation

References

• Basile, J. R., et al. 2004. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer research, 64 (15), 5212–5224.
   PubMed Web of Science ®Google Scholar
• Calkins, H., et al. 2009. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circulation: Arrhythmia and electrophysiology, 2 (4), 349–361.
   PubMed Web of Science ®Google Scholar
• Calkins, H., et al. 2012. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart rhythm, 9, 632–696.
   PubMed Web of Science ®Google Scholar
• Chao, T. F., et al. 2012. Relationship between the CHADS(2) score and risk of very late recurrences after catheter ablation of paroxysmal atrial fibrillation. Heart rhythm, 9 (8), 1185–1191.
   PubMed Web of Science ®Google Scholar
• Chapoval, S. P., et al. 2017. Semaphorins 4A and 4D in chronic inflammatory diseases. Inflammation research, 66 (2), 111–117.
   PubMed Web of Science ®Google Scholar
• Chugh, S. S., et al. 2001. Epidemiology and natural history of atrial fibrillation: clinical implications. Journal of the American college of cardiology, 37 (2), 371–378. PMID: 11216949.
   PubMed Web of Science ®Google Scholar
• den Uijl, D. W., et al. 2011. Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation. American heart journal, 161 (1), 197–203. PMID: 21167354.
   PubMed Web of Science ®Google Scholar
• Gong, H., et al. 2019. sSema4D levels are increased in coronary heart disease and associated with the extent of coronary artery stenosis. Life sciences, 219:329–335.
   PubMed Web of Science ®Google Scholar
• Hussein, A. A., et al. 2011. Natural history and long-term outcomes of ablated atrial fibrillation. Circulation: Arrhythmia and electrophysiology, 4 (3), 271–278.
   PubMed Web of Science ®Google Scholar
• Kato, S., et al. 2011. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Cancer science, 102 (11), 2029–2037.
   PubMed Web of Science ®Google Scholar
• Kılıç, S., et al. 2019. The prevalence and risks of inappropriate combination of aspirin and warfarin in clinical practice: results from WARFARIN-TR study. Balkan medical journal, 36 (1), 17–22.
   PubMed Web of Science ®Google Scholar
• Kirchhof, P., et al. 2016. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 18 (11), 1609–78.
   PubMed Web of Science ®Google Scholar
• Kumanogoh, A., and Kikutani, H. 2010. Semaphorins and their receptors: novel features of neural guidance molecules. Proceedings of the Japan academy, series B, 86 (6), 611–620.
   Google Scholar
• Lu, Q., et al. 2019. Correction: increased levels of plasma soluble Sema4D in patients with heart failure. PLoS one, 14 (3), e0214894.
   PubMed Web of Science ®Google Scholar
• Nakazawa, Y., et al. 2009. Endothelin-1 as a predictor of atrial fibrillation recurrence after pulmonary vein isolation. Heart rhythm, 6 (6), 725–730.
   PubMed Web of Science ®Google Scholar
• Pozzoli, M., et al. 1998. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. Journal of the American college of cardiology, 32 (1), 197–204.
   PubMed Web of Science ®Google Scholar
• Shah, A. N., et al. 2008. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. Journal of cardiovascular electrophysiology, 19 (7), 661–667.
   PubMed Web of Science ®Google Scholar
• Shimano, M., et al. 2008. Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation. Europace, 10 (8), 961–966.
   PubMed Web of Science ®Google Scholar
• Suzuki, K. et al. 2008. Semaphorins and their receptors in immune cell interactions. Nature immunology, 9 (1), 17–23.
   PubMed Web of Science ®Google Scholar
• Tasaka, G., et al. 2012. Semaphorin 4D/Plexin-B1-mediated M-Ras GAP activity regulates actin-based dendrite remodeling through Lamellipodin. Journal of neuroscience, 32 (24), 8293–8305
   PubMed Web of Science ®Google Scholar
• Thomas, L., and Abhayaratna, W. P. 2017. Left atrial reverse remodeling: mechanisms, evaluation, and clinical significance. JACC: Cardiovascular imaging, 10, 65–77.
   PubMed Web of Science ®Google Scholar
• Usui, E., et al. 2015. Recurrence after "long-term success" in catheter ablation of paroxysmal atrial fibrillation. Heart rhythm, 12 (5), 893–898.
   PubMed Web of Science ®Google Scholar
• Watanabe, E., et al. 2006. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. International journal of cardiology, 108 (3), 346–353.
   PubMed Web of Science ®Google Scholar
• Wilber, D. J., et al. 2010. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA, 303 (4), 333–340.
   PubMed Web of Science ®Google Scholar
• Willner, N., et al. 2018. Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure? ESC heart failure, 5 (4), 603–609.
   PubMed Web of Science ®Google Scholar
• Wu, N., et al. 2013. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. International journal of cardiology, 169 (1), 62–72.
   PubMed Web of Science ®Google Scholar
• Wyatt, H. L., et al. 1980. Cross-sectional echocardiography. III. Analysis of mathematic models for quantifying volume of symmetric and asymmetric left ventricles. American heart journal, 100 (6), 821–828.
   PubMed Web of Science ®Google Scholar
• Xiang L., et al. 2015. Serum Soluble semaphorin 4D is associated with left atrial diameter in patients with atrial fibrillation. Medical science monitor, 21, 2912–2917.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al. 2015. Serum Sema4D levels are associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis. International journal of clinical and experimental medicine, 8 (9), 16352–16357.
   PubMed Web of Science ®Google Scholar